
To determine the maximum tolerated dose zzso and dose limiting toxicity zzso of zzso administered in combination with zzso zzso and zzso in children with zzso solid zzso 

The study design included two dose levels zzso of zzso given zzso once daily for 5 consecutive days zzso 30 zzso and zzso 50 zzso combined with zzso zzso zzso on days 1 and 8, zzso 100 zzso on days zzso and zzso zzso on day 1, administered every 21 days for a maximum of 12 zzso 

Thirteen patients zzso and 12 were zzso for toxicity zzso limiting toxicity observed included grade 3 zzso in 1 of 6 patients on zzso and grade 3 colitis in 1 of 6 patients on zzso DL 2 was the determined zzso A total of 87 cycles were zzso zzso was zzso Grade 1-2 zzso occurred in the majority of cycles with grade 3 zzso occurring in only one zzso Grade 2 hypertension developed in two zzso Severe zzso zzso zzso zzso zzso or growth plate abnormalities were not zzso zzso responses were noted in zzso tumor patients and one each zzso and zzso zzso Five patients completed all 12 cycles of protocol zzso 

zzso 50 zzso for 5 days was the zzso when combined with zzso zzso and zzso administered on a 21 day zzso zzso zzso activity was zzso 

zzso zzso zzso 

